May 2026 Research Update

A study this month added real-world reassurance that haploidentical stem cell transplant (a transplant from a partially matched family donor) can work well for many people with PNH linked to bone marrow failure. In 36 transplanted patients, engraftment was high and longer-term survival was reported as strong, with PNH clones clearing in monitored patients. At the same time, the report makes clear that complications like infections and graft-versus-host disease were common parts of the transplant course. [1]

Most patients in this report had aplastic anemia with PNH (AA-PNH), rather than classic PNH, which matters because the transplant goal is often to fix bone marrow failure as well as remove the PNH blood cell population. The study reported a 5-year overall survival of 88.6% and no disease recurrence, and it described PNH clone clearance with a median time of about 3 months in those monitored. In plain terms, this suggests that, in this setting, transplant can replace the blood-forming system and remove the PNH clone, not just reduce symptoms. [1]

The same study also documented that the transplant process carried meaningful risks. Reported issues included acute and chronic graft-versus-host disease and a high rate of early viral infections, with a small number of early deaths and transplant-related mortality. For patients reading this, the key point is that the potential for long-term control comes alongside a challenging short-term period where complications can drive outcomes. [1]

For patients and caregivers, this evidence may matter most for people with AA-PNH who do not have a fully matched donor and are weighing what transplant can accomplish. This report supports that haploidentical transplant can lead to durable survival and can eliminate the PNH clone in at least some monitored patients, but it also underlines that infections and graft-versus-host disease are frequent and can be serious. Because this comes from a single-center retrospective experience, it mainly adds to understanding of what is possible and what risks were seen, rather than settling which approach is best for every patient. [1]

One large genetic study this month made the biology of aplastic anemia clearer by showing that many patients have several different blood cell clones that appear to have evolved to evade immune attack. The study found HLA loss events were frequent and often occurred in multiple separate clones within the same person, and analyses suggested these clones can start years before aplastic anemia is diagnosed. In plain language, this supports the idea that the immune system can shape which blood-forming cells survive over time, creating a patchwork of competing cell populations. [2]

Across 619 patients, clonal hematopoiesis (a situation where some blood cells come from expanded genetic "families" of cells) was detected in 69% of cases. The researchers reported a median of three HLA loss events per patient, and in some people they observed up to 15 HLA-loss clones. This matters because it suggests that immune escape is not a rare exception in aplastic anemia, and it may help explain why the disease can be persistent or variable over time. [2]

The study also reported that HLA loss was less likely to appear alongside CHIP (age-related mutation patterns often discussed in blood disorders), and that longer-lived clones were enriched in early stem and progenitor cells. Put simply, some of these immune-escape clones may be rooted deep in the bone marrow's stem cell compartment, which could help explain why they can last. This is not a test result people routinely receive in clinic, but it adds a clearer picture of how aplastic anemia can evolve at the cell level. [2]

For patients with PNH related to bone marrow failure, this study is most relevant as background understanding, because it focuses on aplastic anemia biology rather than testing a treatment. It helps clarify that immune-driven selection of blood cells can be complex and long-running, with multiple immune-escape clones present in many patients years before diagnosis. What remains uncertain from this report alone is how these findings should be used in day-to-day care, since the study does not link specific clone patterns to specific patient outcomes or decisions. [2]

Two reports this month highlighted that PNH can be hard to recognize and can behave differently depending on which part of the complement system is blocked. A single-patient report showed that standard blood testing can miss PNH in a high-risk situation, while a separate computer modeling study tried to capture both inside-blood-vessel and outside-blood-vessel red cell destruction to explain biomarker changes across drug classes. Together, they add detail to the picture of why symptoms and lab results may not always match expectations. [3] [4]

In the case report, a 60-year-old woman had severe acute kidney injury along with hemolytic anemia, but initial conventional flow cytometry was negative for PNH. Higher-sensitivity testing using a FLAER-based method and gene sequencing (finding a PIGA variant) established the diagnosis, and eculizumab (a C5 complement blocker) was followed by hematologic remission and gradual kidney recovery over several months. In plain terms, this case shows that when suspicion remains high, more sensitive testing can change the answer, and kidney problems can be part of the PNH picture in some people. [3]

The modeling study extended a computer-based representation of the complement pathway to include extravascular hemolysis (red cell breakdown happening outside blood vessels, such as in the spleen or liver). Using data from phase III trials of C5, C3, and factor B inhibitors, the model reproduced patterns of LDH and hemoglobin changes and distinguished expected differences across these drug classes. For patients, the immediate value is mainly research: it is an effort to better explain why lab markers and anemia may respond differently depending on the target, rather than a direct test of a new therapy in people. [4]

These reports may matter now mostly by improving understanding, not by changing standard care on their own. The case report helps clarify that PNH can occasionally show up with prominent kidney injury and that standard flow testing can be falsely reassuring, especially when a patient has already had transfusions or when only a small red-cell clone is present. The modeling work is early-stage research that may matter later if it helps researchers compare complement targets or understand why some patients have ongoing anemia despite control of certain lab markers. [3] [4]